Haemonetics Corporation Common Stock (NY:HAE)

119.79 +1.47 (+1.24%)

Official Closing Price Updated: 7:00 PM EDT, Oct 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Haemonetics Corporation Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Medical Devices & Supplies - Specialty Stocks Q4 Teardown: Integer Holdings (NYSE:ITGR) Vs The Rest

April 09, 2025

Let’s dig into the relative performance of Integer Holdings (NYSE:ITGR) and its peers as we unravel the now-completed Q4 medical devices & supplies - specialty earnings season.

Via StockStory

Medical Devices & Supplies - Specialty Stocks Q3 Recap: Benchmarking STAAR Surgical (NASDAQ:STAA)

April 08, 2025

As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the medical devices & supplies - specialty industry, including STAAR Surgical...

Via StockStory

Q4 Earnings Roundup: Bausch + Lomb (NYSE:BLCO) And The Rest Of The Medical Devices & Supplies - Specialty Segment

April 07, 2025

Looking back on medical devices & supplies - specialty stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Bausch + Lomb (NYSE:BLCO) and its peers.

Via StockStory

How Do Investors Really Feel About Haemonetics? ↗

March 11, 2025

Via Benzinga

(HAE) - Analyzing Haemonetics's Short Interest ↗

February 18, 2025

Via Benzinga

Haemonetics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) ↗

February 07, 2025

Via Benzinga

Earnings Scheduled For February 6, 2025 ↗

February 06, 2025

Via Benzinga

Q4 Earnings Highs And Lows: Haemonetics (NYSE:HAE) Vs The Rest Of The Medical Devices & Supplies - Specialty Stocks

April 04, 2025

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Haemonetics (NYSE:HAE) and the best and...

Via StockStory

3 Reasons to Avoid HAE and 1 Stock to Buy Instead

April 02, 2025

Haemonetics has gotten torched over the last six months - since October 2024, its stock price has dropped 20.1% to $63.39 per share. This was partly due to its softer quarterly results and might have...

Via StockStory

Topics Supply Chain

3 Healthcare Stocks Walking a Fine Line

March 20, 2025

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of...

Via StockStory

Topics Stocks

How Is The Market Feeling About Haemonetics? ↗

January 31, 2025

Via Benzinga

The Latest Analyst Ratings For Haemonetics ↗

December 04, 2024

Via Benzinga

Deep Dive Into Haemonetics Stock: Analyst Perspectives (7 Ratings) ↗

November 08, 2024

Via Benzinga

NYSE:HAE is not too expensive for the growth it is showing. ↗

October 31, 2024

While growth is established for NYSE:HAE, the stock's valuation remains reasonable.

Via Chartmill

Demystifying Haemonetics: Insights From 5 Analyst Reviews ↗

March 18, 2025

Via Benzinga

HAEMONETICS CORP/MASS (NYSE:HAE) is probably undervalued for the fundamentals it is displaying. ↗

March 11, 2025

HAEMONETICS CORP/MASS has caught the attention as a great value stock. NYSE:HAE excels in profitability, solvency, and liquidity, all while being very reasonably priced.

Via Chartmill

Medical Devices & Supplies - Specialty Stocks Q4 In Review: Globus Medical (NYSE:GMED) Vs Peers

March 11, 2025

Looking back on medical devices & supplies - specialty stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Globus Medical (NYSE:GMED) and its peers.

Via StockStory

A Look Back at Medical Devices & Supplies - Specialty Stocks’ Q3 Earnings: STAAR Surgical (NASDAQ:STAA) Vs The Rest Of The Pack

February 28, 2025

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at STAAR Surgical (NASDAQ:STAA) and the best...

Via StockStory

Despite its growth, NYSE:HAE remains within the realm of affordability. ↗

October 10, 2024

HAEMONETICS CORP/MASS (NYSE:HAE), a growth stock which is not overvalued.

Via Chartmill

What Analysts Are Saying About Haemonetics Stock ↗

September 10, 2024

Via Benzinga

Bausch + Lomb (BLCO) Reports Earnings Tomorrow: What To Expect

February 18, 2025

Eyecare company Bausch + Lomb (NYSE:BLCO) will be announcing earnings results tomorrow morning. Here’s what to expect.

Via StockStory

Inspire Medical Systems (INSP) To Report Earnings Tomorrow: Here Is What To Expect

February 09, 2025

Medical technology company Inspire Medical Systems (NYSE:INSP) will be reporting results tomorrow after market close. Here’s what you need to know.

Via StockStory

For those who appreciate value investing, NYSE:HAE is a compelling option with its solid fundamentals. ↗

February 07, 2025

HAEMONETICS CORP/MASS is a hidden gem, featuring undervaluation and robust fundamentals. NYSE:HAE showcases decent financial health and profitability, coupled with an attractive price.

Via Chartmill

Haemonetics (NYSE:HAE) Misses Q4 Revenue Estimates

February 06, 2025

Blood products company Haemonetics (NYSE:HAE). fell short of the market’s revenue expectations in Q4 CY2024 as sales rose 3.7% year on year to $348.5 million. Its non-GAAP profit of $1.19 per share was...

Via StockStory

Earnings To Watch: Haemonetics (HAE) Reports Q4 Results Tomorrow

February 05, 2025

Blood products company Haemonetics (NYSE:HAE). will be announcing earnings results tomorrow before the bell. Here’s what to expect.

Via StockStory

While growth is established for NYSE:HAE, the stock's valuation remains reasonable. ↗

December 13, 2024

For those who appreciate growth without the sticker shock, HAEMONETICS CORP/MASS (NYSE:HAE) is worth considering.

Via Chartmill

This Constellation Brands Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗

December 06, 2024

Via Benzinga

For those who appreciate growth without the sticker shock, NYSE:HAE is worth considering. ↗

November 21, 2024

In the world of growth stocks, NYSE:HAE shines as a value proposition.

Via Chartmill

Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer

September 24, 2024

From Aligos Therapeutics

Via GlobeNewswire

NYSE:HAE stands out as a growth opportunity that won't break the bank. ↗

September 18, 2024

Investors should take note ofHAEMONETICS CORP/MASS (NYSE:HAE), a growth stock that remains attractively priced.

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.